EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Multizentrische Studie

The safety, tolerability, pharmacokinetics and pharmacodynamics of GZR18 in healthy American and Chinese adult subjects

Yue Liu, Wei Chen, Xuemei He iD, Anshun He iD, Liyuan Zhao, Tian Xie, Yue Li, Jing Zhao, Allen Hunt, Aixin Shi, Zhong-Ru Gan

Diabetes, Obesity and Metabolism · 2025

DOI: 10.1111/dom.16285 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Yue Liu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Trial Center, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijin…. Hauptthemen laut MEDLINE: Hypoglycemic Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: National High Level Hospital Clinical Research Funding, Gan & Lee pharmaceuticals Co, Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

GZR18, a novel long‐acting GLP‐1 receptor agonist, has demonstrated substantial metabolic improvements in diabetic and obese animal models. The present studies aimed to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of the ascending dose of GZR18 in healthy American and Chinese subjects. Materials and Methods In these phases 1, randomized, double‐blind, placebo‐controlled, sequential, dose‐escalation US and Chinese studies, healthy American and Chinese adults with similar age were enrolled to once‐weekly subcutaneous injection of GZR18 or placebo. The studies included three cohorts of male American subjects (cohorts US‐1–3) and six cohorts of Chinese subjects (cohorts CN‐1–6, male and female), each with a specified target dose of GZR18 ranging from 1 to 50 μg/kg (1–10 μg/kg for US study and 5–50 μg/kg for Chinese study). The primary endpoints were the safety and tolerability of GZR18. Blood samples were collected for PK and PD analysis of GZR18 before and after dosing. A population PK analysis of GZR18 was conducted to ascertain whether there are ethnic PK differences between American and Chinese adults.

Results

The exposure of GZR18 was comparable between healthy American and Chinese subjects, with the geometric mean ratio between the two populations for AUC 0‐t and C max close to 1. A dose‐dependent increase in AUC 0–t and C max occurred in both populations. The median time to maximum plasma concentrations ( T max ) in American subjects ranged from 72 to 96 h, and the mean T max ranged from 60 to 72 h in Chinese subjects. The half‐life of GZR18 was approximately 7 days in both American and Chinese subjects. Evident body weight reduction was observed in GZR18 treatment groups in Chinese subjects (cohorts CN‐3–6 on Day 15, −1.25 to −1.86 kg; −1.88% to −3.11%). No deaths, serious adverse events or hypoglycaemia were reported. Decreased appetite and nausea were the most frequently reported treatment‐emergent adverse events, observed in Chinese study and mild in severity. The safety profile of GZR18 was generally consistent with the same class of drugs.

Conclusions

GZR18 demonstrates good tolerability in healthy American and Chinese subjects. No ethnic differences were observed between healthy American and Chinese subjects. The safety, PK and PD profiles of GZR18 support its further clinical evaluation for glycaemic and body weight control.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypoglycemic AgentsAdultFemaleHumansMaleMiddle AgedYoung AdultChinaDose-Response Relationship, DrugDouble-Blind MethodGlucagon-Like Peptide-1 ReceptorHealthy VolunteersInjections, SubcutaneousUnited StatesEast Asian People

Stichwörter der Autor:innen

GZR18diabetesglucagon‐like peptide‐1 receptor agonistobesitypharmacokinetics

Substanzen

GLP1R protein, humanGlucagon-Like Peptide-1 ReceptorHypoglycemic Agents

Autor:innen und Institutionen

  • Clinical Trial Center, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
  • Gan & Lee Pharmaceuticals, Beijing, China.
  • Celerion, Lincoln, Nebraska, USA.

ORCID-Profile: Xuemei He, Anshun He

Förderung

  • National High Level Hospital Clinical Research Funding
  • Gan & Lee pharmaceuticals Co, Ltd

Zitieren

APA

Liu, Y., Chen, W., He, X., He, A., Zhao, L., Xie, T., Li, Y., Zhao, J., Hunt, A., Shi, A., & Gan, Z. R. (2025). The safety, tolerability, pharmacokinetics and pharmacodynamics of GZR18 in healthy American and Chinese adult subjects. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16285

Vancouver

Liu Y, Chen W, He X, He A, Zhao L, Xie T, et al. The safety, tolerability, pharmacokinetics and pharmacodynamics of GZR18 in healthy American and Chinese adult subjects. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16285

BibTeX
@article{Liu2025,
  author = {Liu, Yue and Chen, Wei and He, Xuemei and He, Anshun and Zhao, Liyuan and Xie, Tian and Li, Yue and Zhao, Jing and Hunt, Allen and Shi, Aixin and Gan, Zhong-Ru},
  title = {The safety, tolerability, pharmacokinetics and pharmacodynamics of GZR18 in healthy American and Chinese adult subjects},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  doi = {10.1111/dom.16285}
}
Kostenlos starten →